Switch theme
Sign up to access all valuation multiples
Transgene SA is a biotechnology company. The Company conducts its business exclusively in the clinical research and development of therapeutic vaccines and immunotherapeutic products. The company's clinical-stage programs are TG4010 for non-small cell lung cancer and Pexa-vec for liver cancer. Its product pipeline includes TG4001, TG1050, TG6002 etc. It is engaged in clinical research and development of therapeutic vaccines and immunotherapeutic products. The majority of its operations is located in France.
1979
167
LTM Revenue $18.1M
LTM EBITDA -$24.9M
$73.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Transgene has a last 12-month revenue of $18.1M and a last 12-month EBITDA of -$24.9M.
In the most recent fiscal year, Transgene achieved revenue of $0.3M and an EBITDA of -$33.3M.
Transgene expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Transgene valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.3M | $0.3M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$22.1M | -$33.3M | XXX | XXX | XXX |
| EBITDA Margin | -1739% | -10101% | XXX | XXX | XXX |
| Net Profit | -$35.2M | -$24.0M | XXX | XXX | XXX |
| Net Margin | -2771% | -7273% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Transgene's stock price is EUR 1 (or $1).
Transgene has current market cap of EUR 84.9M (or $91.2M), and EV of EUR 68.3M (or $73.3M).
See Transgene trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $73.3M | $91.2M | XXX | XXX | XXX | XXX | $-0.19 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Transgene has market cap of $91.2M and EV of $73.3M.
Transgene's trades at 4.0x LTM EV/Revenue multiple, and -2.9x LTM EBITDA.
Analysts estimate Transgene's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Transgene and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $73.3M | XXX | XXX | XXX |
| EV/Revenue | 222.4x | XXX | XXX | XXX |
| EV/EBITDA | -2.2x | XXX | XXX | XXX |
| P/E | -2.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -2.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpTransgene's NTM/LTM revenue growth is 82%
Transgene's revenue per employee for the last fiscal year averaged $2K, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Transgene's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Transgene's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Transgene and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -74% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -10101% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 51% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -10018% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $2K | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1190% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 11165% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 11724% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Transgene acquired XXX companies to date.
Last acquisition by Transgene was XXXXXXXX, XXXXX XXXXX XXXXXX . Transgene acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Transgene founded? | Transgene was founded in 1979. |
| Where is Transgene headquartered? | Transgene is headquartered in France. |
| How many employees does Transgene have? | As of today, Transgene has 167 employees. |
| Who is the CEO of Transgene? | Transgene's CEO is Dr. Alessandro Riva, M.D.. |
| Is Transgene publicy listed? | Yes, Transgene is a public company listed on PAR. |
| What is the stock symbol of Transgene? | Transgene trades under TNG ticker. |
| When did Transgene go public? | Transgene went public in 1998. |
| Who are competitors of Transgene? | Similar companies to Transgene include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Transgene? | Transgene's current market cap is $91.2M |
| What is the current revenue of Transgene? | Transgene's last 12-month revenue is $18.1M. |
| What is the current EBITDA of Transgene? | Transgene's last 12-month EBITDA is -$24.9M. |
| What is the current EV/Revenue multiple of Transgene? | Current revenue multiple of Transgene is 4.0x. |
| What is the current EV/EBITDA multiple of Transgene? | Current EBITDA multiple of Transgene is -2.9x. |
| What is the current revenue growth of Transgene? | Transgene revenue growth between 2023 and 2024 was -74%. |
| Is Transgene profitable? | Yes, Transgene is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
